Eli Lilly’s experimental Alzheimer’s medicine donanemab showed some of the best early results that pharmaceutical researchers have seen in the field. What distinguishes many researchers is whether or not it is a cause for excitement.
The results, published Saturday at the International Conference on Alzheimer’s and Parkinson’s Diseases, and published in the New England Journal of Medicine, come from a Phase 2 study, commonly used by pharmaceutical companies to to test whether a drug earns in a larger phase 3 study. may result in approval. While leading results are set out in a press release from Lilly, it is a high watermark for studies in Alzheimer’s. This is the first time that a phase 2 study of a drug trying to slow down Alzheimer’s, and not just the symptoms of patients, can reduce it.
Unlock this article by subscribing to STAT + and enjoy your first 30 days for free!
START
What is it?
STAT + is the premium entry service of STAT for in-depth coverage and analysis of biotechnology, pharmaceutical, policy and life science coverage. Our award-winning team covers news about Wall Street, policy developments in Washington, early scientific breakthroughs and results of clinical trials, and disruption of health care in Silicon Valley and beyond.
What is included?
- Daily reporting and analysis
- The most comprehensive operational coverage of a powerhouse of reporters
- Subscriber newsletters only
- Daily newsletters to inform you about the most important industry news of the day
- STAT + talks
- Weekly opportunities to engage in live video chats with our reporters and leading industry experts
- Exclusive business opportunities
- Premium access to online events for just subscribers across the country
- The best reporters in the industry
- The most trusted and well-connected newsroom in the healthcare industry
- And much more
- Exclusive interviews with industry leaders, profiles and premium tools, such as our CRISPR Trackr.